Clinical trials: PERIPHERAL VASCULAR DISEASE
Peripheral Artery Disease
CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings
The objective of this study is to evaluate the safety and efficacy of the CLiRpath® Photoablation Atherectomy System consisting of the Bias Sheath guiding catheter, in combination with the available CLiRpath® Excimer Laser…
- Trial name
- CELLO (NCT00595959)
- Testing
- CLiRpath Photoablation System
- Volunteers
- 65 people
- Sponsor
- Spectranetics Corporation
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche
Peripheral Arterial Disease
Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease
An exploratory evaluation of the efficacy and safety of CLZ-BM3D for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery
- Trial name
- NCT05759819
- Testing
- Standard stenting
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Otsuka Medical Devices Co., Ltd. Japan
Carotid Atherosclerosis, Peripheral Arterial Disease
Non-invasive Computer-Aided Phenotyping of Vasculopathy
The investigators use MRI and/or CT to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an…
- Trial name
- Q-CAMP (NCT02143102)
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Elucid Bioimaging Inc.
Peripheral Arterial Disease
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
This study is designed to evaluate the safety and efficacy of autologous Vascular Repair Cells (VRC) for patients with peripheral arterial disease as a treatment for critical limb ischemia.
- Trial name
- RESTORE-CLI (NCT00468000)
- Testing
- Ixmyelocel-T
- Where
- 20 sites in United States
- Volunteers
- 86 people
- Sponsor
- Vericel Corporation
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Peripheral Artery Disease
Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system
Non-randomized multicenter post-market study to confirm the long-term safety and effectiveness of the CE-approved Camouflage-coated self-expandable RESISTANT Camouflage stent system for revascularization of de novo stenotic…
- Trial name
- RECAM (NCT02011984)
- Where
- 5 sites in Germany, Italy
- Volunteers
- 120 people
- Sponsor
- Eucatech AG
Foot Ulcer, Diabetic
Approaches to Foot Complication Prevention: A Survey of Diabetes Educators
The purpose of the survey is to assess the knowledge base, role in management, and resources available to diabetes educators regarding foot complication prevention within a variety of healthcare settings.
- Trial name
- NCT04400344
- Testing
- No intervention
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Podimetrics, Inc.
Peripheral Arterial Disease
Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System.
- Trial name
- TOBA III (NCT02802306)
- Testing
- Tack Endovascular System
- Where
- 17 sites in Austria, Belgium and 2 more
- Volunteers
- 201 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Atrial Fibrillation, Ischemic Stroke
AMPLATZER Cardiac Plug Clinical Trial
The objective of this study is to evaluate the safety and effectiveness of the ACP in subjects with nonvalvular atrial fibrillation by demonstrating that the device is non-inferior to optimal medical therapy (OMT) with respect to…
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
- Trial name
- NCT01118299
- Testing
- AMPLATZER Cardiac Plug
- Where
- 18 sites in United States
- Volunteers
- 97 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease
"Unifuzol®" in Patients With Peripheral Arterial Disease
The present study is a multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating atherosclerosis of the lower extremities.
- Trial name
- NCT03861416
- Testing
- L-arginine 1.4% 500 ml
- Where
- 19 sites in Russia
- Volunteers
- 360 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Peripheral Arterial Disease
Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration During Lower Extremity Tibial Interventions
Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration during Lower Extremity Tibial Interventions
- Trial name
- Protexus 1 (NCT06929832)
- Volunteers
- 20 people
- Sponsor
- Protexa Endovascular, Inc.
Peripheral Arterial Disease
A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Evaluation of the Gore(R) VIABAHN BX for the treatment of arterial occlusive disease in the common and/or external iliac arteries.
- Trial name
- VBXFLEX (NCT02080871)
- Testing
- Stenting of the Common and/or External Iliac Arteries
- Where
- 27 sites in United States, New Zealand
- Volunteers
- 134 people
- Sponsor
- W.L.Gore & Associates
Peripheral Arterial Disease
Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)
Shockwave Medical, Inc. intends to conduct a prospective, single-arm, multi-center, clinical study designed to evaluate the safety and performance of the Shockwave Lithoplasty™ System in subjects with moderate to heavily…
- Trial name
- NCT02369848
- Testing
- Shockwave Lithoplasty System
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Shockwave Medical, Inc.
Peripheral Vascular Diseases
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.
- Trial name
- VIPER (NCT00541307)
- Testing
- Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- W.L.Gore & Associates
Peripheral Vascular Disease
Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease
This is a phase II, multicenter, randomized, double-blind, placebo-controlled trial in which subjects with intermittent claudication (IC) will be randomized to receive a single treatment of VLTS-934 (84 mL, or a total of 420 mg…
- Trial name
- NCT00113009
- Testing
- VLTS-934
- Where
- 32 sites in United States
- Volunteers
- 148 people
- Sponsor
- Valentis
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Peripheral Artery Disease
AcoArt IV / SFA in China:Drug-eluting Balloon for SFA Angioplasty Evaluation in China
The registry is a prospective, multicenter, single arm post-market real-world registry in China assessing the clinical use, safety and outcomes of the Orchid 035 DCB Catheter in the Superficial Femoral Artery (SFA) and Popliteal…
- Trial name
- NCT03267056
- Testing
- drug eluting balloon catheter (trade name: Orchid)
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Acotec Scientific Co., Ltd
Peripheral Arterial Disease
Safety and Efficacy of the QBX Peripheral Balloon Expandable Stent System in Peripheral Artery Disease (PAD)
This study aims to evaluate the safety and performance of the QBX stent system in the treatment of PAD by reporting of peri- and postoperative complications, including major adverse vascular events (MAVE), Vascular Access Site…
- Trial name
- QBX-RADAR (NCT05799131)
- Testing
- QBX (5F/6F) Peripheral Balloon Expandable Stent System
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- QualiMed Innovative Medizinprodukte GmbH
Peripheral Arterial Disease
Safety Trial Of CTX Cells In Patients With Lower Limb Ischaemia
The primary objective of the Phase I ascending dose trial is to investigate the safety and tolerability of intramuscular (gastrocnemius) injections of human neural stem cell product, CTX, in patients with peripheral arterial…
- Trial name
- NCT01916369
- Testing
- CTX DP
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- ReNeuron Limited